Treatment of Pancreatic Cancer Modesto CA

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Walter John Schimon, MD
(209) 521-0870
1541 Florida Ave Ste 306
Modesto, CA
Specialties
Urology, General Surgery
Gender
Male
Education
Medical School: Univ Of Ks Sch Of Med, Kansas City Ks 66103
Graduation Year: 1984

Data Provided by:
Phillip H Beck
(209) 577-3388
1541 Florida Ave
Modesto, CA
Specialty
Urology

Data Provided by:
Parminder Singh Sethi, MD
(209) 521-0870
1541 Florida Ave Ste 306
Modesto, CA
Specialties
Urology
Gender
Male
Education
Medical School: Christian Med Coll, Punjab Univ, Ludhiana, Punjab, India
Graduation Year: 1979

Data Provided by:
Brian T Mc Caffrey, MD
(209) 634-8556
1541 Florida Ave Ste 306
Modesto, CA
Specialties
Urology
Gender
Male
Languages
Spanish
Education
Medical School: Univ Coll Dublin, Nat'L Univ Of Ireland, Fac Of Med, Dublin
Graduation Year: 1967
Hospital
Hospital: Doctors Med Ctr, Modesto, Ca; Emanuel Med Ctr, Turlock, Ca
Group Practice: Valley Associated Urology Medical Group

Data Provided by:
Brian T Mc Caffrey
(209) 577-3388
1541 Florida Ave
Modesto, CA
Specialty
Urology

Data Provided by:
Mark Saleh, MD
(209) 521-0870
1541 Florida Ave Ste 301
Modesto, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Toronto, Fac Of Med, Toronto, Ont, Canada
Graduation Year: 1994

Data Provided by:
Walter J Schimon
(209) 521-0870
1541 Florida Ave
Modesto, CA
Specialty
Urology

Data Provided by:
Curtis Richard DeWar
(209) 577-3388
1541 Florida Ave
Modesto, CA
Specialty
Urology

Data Provided by:
Phillip Henry Beck, MD
(209) 521-0870
1541 Florida Ave Ste 306
Modesto, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Co Sch Of Med, Denver Co 80262
Graduation Year: 1970

Data Provided by:
Curtis Richard Dewar, MD
(209) 521-0870
1541 Florida Ave Ste 306
Modesto, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Mi Med Sch, Ann Arbor Mi 48109
Graduation Year: 1973

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com